Alan Davis’ Post

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science. The company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.   Recently, AstraZeneca unveiled its new Bold Ambition during the Global Investor’s Day setting the stage for 2030! Aspiring to be pioneers in science, focused on transform patient outcomes, by 2030, globally we will deliver 20 new medicines, industry leading growth and aim to be carbon negative.   In India, we have recently announced our financial results for FY 2023-24 with 29% growth in revenue, which is one of our strongest years of performance. We owe this our talented, committed and passionate group of employees who go above and beyond in terms of achieving greater milestones every single day to transform the lives of patients. Proud to be part of a company that is unlocking the power of what science can do for people, society and the planet.   Read more here: https://lnkd.in/gtJHuUeK   #ScienceCan #AZProud

EXCERPTS: AstraZeneca Plc is fleshing out plans for a manufacturing network that will independently supply drugs to major markets as the U.S. pushes to reduce the pharma industry’s reliance on China. The UK drugmaker will make the same medicine at different facilities to serve various markets separately, Chief Executive Officer Pascal Soriot said in an interview from the sidelines of the Boao Forum for Asia. The individualized approach will take place regardless of where a drug originated, according to Soriot. “Those will be very segmented activities,” he said. “The issues of invention, development and manufacturing are disconnected.” The proposed U.S. bill names WuXi AppTec Co. and Wuxi Biologics, among the biggest research, development and manufacturing companies in the world, making them major casualties in the effort to cut Chinese companies out of drug supply chains. The Biosecure Act is expected to affect the broader pharmaceutical industry as well, as the WuXi businesses provide essential services for most of the world’s top drugmakers, including Astra. Astra recently announced a $475 million new production facility in the eastern city of Wuxi, saying it will make innovative medicines for China and other markets. Construction is also underway for a $700 million manufacturing site in the coastal city Qingdao for respiratory medicines. Soriot also announced a partnership with a subsidiary of Chinese vaccine maker Shenzhen Kangtai Biological Products Co. in Beijing on Tuesday. The initiative is targeted at developing and manufacturing vaccines for the local population, he said. Separating manufacturing along geopolitical fault lines hasn’t stopped Astra from scouting for promising drug candidates in China. The company inked seven deals worth as much as $6 billion with local companies last year to jointly develop drug candidates for diseases from obesity to cancer. The acquisition of Shanghai-based Gracell Biotechnologies Inc. will play an important role in how the company develops new cell therapies in the future, Soriot said. At the same time, Astra also invested in a manufacturing site in Maryland to make cell therapies. COMMENT: As anticipated. Others will follow. Welcome to a brave new (bifurcated) world. I wonder who gets to serve booming Southeast Asia?

Let us take a look at the global pharma industry R&D pipeline: Pfizer is currently leading the pack with over 100 programs, including a strong emphasis on oncology, but also vaccines and metabolic & inflammatory indications. And also AstraZeneca stands out with its impressive suite of Phase 3 assets, signaling a variety of launches to come to market in the near future. The company expects 10 programs thereof to have “blockbuster potential.” The graph also points to the strong global footprint of the industry and its innovation capability. The pipeline is not dominated by players only from one continent. While the USA are famous for very strong contributions to pharma R&D spend as well as innovation output, the top 10 list also features players from Asia and Europe. And of course, the companies operate internationally with integrated innovation networks inside and outside of their own organizations and HQ countries. Roland Berger Belgium happily supports local and international Pharmaceutical players navigate their most critical challenges. Please feel free to contact our experts: Grégoire Tondreau Astrid Böhlke Maxime Descy Michael Baur #RolandBerger #RBHealthBelgium #Innovation #Pharma #LifeScience #R&D

Thoughts on this? >> BioCentriq names ex-Resilient exec as new CEO; Sanofi, AstraZeneca boost Beyfortus production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #biotech #productmarketing

AstraZeneca counts to biggest companies in #PHARMA industry and I am happy that it started to talk INDUSTRY 5.0. I do believe that PASCAL SORION, the new CEO will insist on the implementation of INDUSTRY 5.0 principles into the company policy and development framework and I would be happy if the membership in the INDUSTRY 5.0 STRATEGIC ALLIANCE will be part of the journey. INDUSTRY 5.0 AMBASSADORS NETWORK Industry 5.0

Thoughts on this? >> BioCentriq names ex-Resilient exec as new CEO; Sanofi, AstraZeneca boost Beyfortus production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #pharmaceutical #healthcare

AstraZeneca 𝐡𝐚𝐬 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝 𝐚𝐧 𝐚𝐦𝐛𝐢𝐭𝐢𝐨𝐮𝐬 𝐠𝐨𝐚𝐥 𝐭𝐨 𝐛𝐨𝐨𝐬𝐭 𝐢𝐭𝐬 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐛𝐲 𝟕𝟓% 𝐭𝐨 $𝟖𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎. This growth is expected to be driven by the launch of 20 new medicines and the expansion of its current oncology, biopharmaceuticals, and rare disease portfolios. 𝐂𝐄𝐎 𝐏𝐚𝐬𝐜𝐚𝐥 𝐒𝐨𝐫𝐢𝐨𝐭, who has significantly revitalized the company's drug pipeline over the past decade, highlighted that many of these new medicines could each generate over $5 billion in peak year revenues. Despite facing patent expirations on some key drugs, AstraZeneca plans to invest in new technologies and platforms to sustain its growth beyond 2030. Analysts are keenly watching the company's investor day event for detailed insights into its pipeline assets and their market potential. https://lnkd.in/dZxxjuvF #PharmaGrowth #AstraZeneca #BiotechInnovation #NewMedicines #HealthcareInvestment #pharma

GSK and Flagship Pioneering tie up in a multibillion-dollar deal to develop as many as 10 new drugs in a deal that could pay more than $7 billion to firms supported by the venture capital biotech. Flagship Pioneering which created mRNA Covid-vaccine maker Moderna Inc., and GSK will jointly put $150 million upfront toward exploring new respiratory and immunology treatments GSK will commit as much as $720 million for each of the 10 drugs, including upfront payments, if they reach all of their development and commercial milestones. Chief Executive Officer Emma Walmsley is working to hone GSK’s product portfolio, and the deal with Flagship Pioneering is aimed at fields where the drug giant has been working to expand. Earlier this year, GSK agreed to buy US biotech Aiolos Bio Inc. for as much as $1.4 billion to gain its experimental asthma drug. But will it help GlaxoSmithKline to come out of Zantac shock??!! We have to wait and watch. US Pharma companies are as dangerous as Mafia. They will not allow the Pharma Companies of other countries to raise heads....GlaxoSmithKline is not an exception...But this time GSK has moved wisely...tying up with some American Companies....

🚀 Big Pharma Boosts Investment in France! Sanofi, Pfizer, GSK and AstraZeneca are ramping up their commitment to France with nearly €2 billion in investments! Here's the breakdown: 💼 Sanofi Leads the Charge: Investing over €1 billion to expand biologics production, doubling capacity in Vitry-sur-Seine and injecting €100 million into the Le Trait site in Normandy. 🔬 Pfizer's Push: Allocating €500 million to bolster R&D and clinical trials, focusing on sickle cell disease and multiple myeloma, while also enhancing manufacturing capabilities. 💊 AstraZeneca's Expansion: Injecting €360 million into its manufacturing facility in Dunkirk, specializing in inhaled devices, to further support its operations and workforce. GSK is set to unveil new investments in the country later this week. These investments not only drive innovation and growth but also underscore France's attractiveness for global pharma players. #Pharma #Executivesearch #France

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation